abstract |
The present disclosure relates to compounds and methods that may be useful as inhibitors of KDM1A for the treatment of diseases. Methods of inhibiting KDM1A for the treatment of diseases such as acute myelogenous leukemia, methods of increasing gamma globin gene expression, and methods of inducing cancer cell differentiation in human or animal subjects are also provided. |